Hi Bec,
I couldn’t find any current trial info. on ICL670 in the US, but there is a trial taking place in Toronto,Ontario…..(worth a try?)
—————————————————————————————————-
A multi-center, open-label, non-comparative, phase II trial on efficacy and safety of ICL670 (5-40 mg/kg/day) given for at least 1 year to patients with chronic anemias and transfusional hemosiderosis
People with transfusion dependent anemia require regular red blood cell transfusions to keep them healthy. Repeated blood cell transfusions, and the breakdown of red blood cells, results in the build-up of iron in vital organs. Subcutaneous or intravenous Desferol is currently used to get rid of extra iron in the body. However, this therapy can be painful and difficult to take. An oral chelator, such as ICL670, would be easier to administer and may improve compliance and quality of life. The purpose of this study is to study the effects if ICL670 treatment on the liver iron content as assessed by liver biopsy after one year of treatment.
For more information, please contact Jamie Chow at jamie.chow@uhn.on.ca or at (416) 340-4800 ext.
6069.
.
